WHAT IS CLAIMED IS:

1. A composition comprising an aqueous solution comprising:

(i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence, and

(ii) as an adjuvant of immunity, a surfactant, or a mixture of surfactants, having an overall HLB number of between 5 and 15.

2. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise modified fatty substances.

3. The composition as defined in Claim 2, in which the surfactant or mixture of surfactants comprise modified fatty substances having an overall HLB number of between 6 and 14.

4. The composition as defined in Claim 2, in which the modified fatty substance is an alkoxylated derivative of an oil or an alkoxylated derivative of an alkyl ester of an oil.

5. The composition as defined in Claim 4, in which the modified fatty substance is an ethoxylated derivative of an oil having a number of EOs of between 1 and 60.

6. The composition as defined in Claim 3, in which the modified fatty substance is an alkoxylated derivative of corn oil, or a mixture of alkoxylated derivatives of corn oil, having an overall HLB number of between 10 and 14.

7. The composition as defined in Claim 3, in which the modified fatty substance is an ethoxylated derivative of castor oil, or a mixture of alkoxylated derivatives of castor oil, having an overall HLB of between 7 and 10.

8. The composition as defined in Claim 6, in which the modified fatty substance is an ethoxylated derivative of corn oil having a number of EOs of

between 20 and 40.

9. The composition as defined in Claim 7, in which the modified fatty substance is a mixture of ethoxylated derivatives of castor oil having a number of EOs equal to 7, and of ethoxylated derivatives of castor oil having a number of EOs equal to 60.

10. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise an alkoxylated derivative of an ester of a fatty acid and of a polyol or the alkoxylated derivative of an ether of a fatty alcohol and of a polyol.

11. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise an ethoxylated derivative of an ester of a fatty acid and of a polyol, or the ethoxylated derivative of an ether of a fatty alcohol and of a polyol, having a number of EOs of between 1 and 60.

12. The composition as defined in Claim 10, in which the surfactant, or the mixture of surfactants, has an overall HLB number of between 10 and 14.

13. The composition as defined in Claim 11, in which the surfactant is an ethoxylated derivative of mannitan oleate having a number of EOs of between 5 and 15.

14. The composition as defined in Claim 1, further comprising an immunostimulant.

15. The composition as defined in Claim 1, further comprising one or more water-soluble metal cation organic salts.

16. The composition as defined in Claim 1, further comprising a sympathomimetic compound comprising a catecholamine, an amphetamine, a phenylisopropylamine or a tyramine.

17. The composition as defined in Claim 1, in a form suitable for administration of said at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence to a human or an animal.

18. A medicinal product comprising the composition according to Claim 17, wherein said at least one antigen or said at least one in vivo generator of a compound comprising an amino acid sequence is present in said composition in an amount effective for treating or for preventing infectious and/or functional diseases.

19. A method of providing an adjuvant effect to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants, said surfactant or mixture of surfactants having an overall HLB number of between 5 and 15.

20. A method of providing an adjuvant effect to a vaccine as defined in Claim 19, wherein said vaccine does not include an oily phase.

21. The composition as defined in Claim 10, wherein said alkoxylate derivative is an alkoxylated fatty acid triglyceride, a polyglycerol alkoxylated ester of a fatty acid, an alkoxylated ester of a fatty acid with a hexol or the alkoxylated ester of a fatty acid with a hexol anhydride.

22. The composition as defined in Claim 21, wherein said hexol is sorbitol or mannitol.

23. The composition as defined in Claim 22, wherein said hexol anhydride is sorbitan or mannitan.

24. The composition as defined in Claim 10, wherein the surfactant or mixture of surfactants has an overall HLB number of between 12 and 13.5.

25. The composition as defined in Claim 13, in which the number of EOs is between 7 and 11.

26. The composition as defined in Claim 14, wherein said immunostimulant is AVRIDINE®, an MDP derivative, a mycolic acid derivative or a lipid A derivative.

27. The composition as defined in Claim 15, wherein said water-soluble metal cation organic salt is calcium gluconate, manganese gluconate, aluminum salicylate or soluble aluminum acetate.

28. The composition as defined in Claim 16, wherein said sympathomimetic compound is ephedrine, isoproterenol, L-Epinephrine, levarterenol, phenylephedrine, or salbutamol.

29. The medicinal product as defined in Claim 18, wherein said disease is one engendered by a virus, a microorganism or a parasite.

30. The method as defined in Claim 19, wherein said vaccine is suitable for a mucosal vaccination.

31. The method as defined in Claim 30, wherein said vaccine is suitable for application orally, nasally, rectally or vaginally.

add A'

add B'